Valuation: Nutriband Inc.

Market Cap 38.66M 33.49M 31.35M 28.62M 53.82M 3.69B 54.73M 368M 144M 1.84B 145M 142M 6.16B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 34.33M 29.74M 27.84M 25.41M 47.79M 3.28B 48.6M 327M 128M 1.64B 129M 126M 5.47B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 35 31/12/2015
Chief Executive Officer 52 -
Director of Finance/CFO 77 01/09/2020
Director TitleAgeSince
Chairman 52 20/01/2022
Director/Board Member 48 30/06/2018
Director/Board Member 38 30/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%-1.10% - - 38.17M
+1.01%+2.43%-18.29%+4.75% 188B
+1.42%+4.61%-2.37%+9.10% 114B
+2.73%+8.27%+17.09%+78.51% 62.02B
+2.38%+3.92%+35.52%+60.21% 55.26B
+0.99%+6.58%-6.25%-34.56% 48.93B
+2.14%+2.54%+13.53%-20.96% 33.08B
+3.64%-13.42% - - 29.66B
-0.22%+0.99%+45.81%-12.21% 24.78B
+8.53%+11.42%-5.85%+18.17% 23.91B
Average +2.03%+3,263.60%+9.90%+12.88% 64.45B
Weighted average by Cap. +1.44%+2,681.73%+0.82%+14.31%

Financials

2025 2026
Net sales 2.14M 1.85M 1.74M 1.58M 2.98M 204M 3.03M 20.36M 7.97M 102M 8.03M 7.86M 341M 2.04M 1.76M 1.65M 1.51M 2.84M 194M 2.88M 19.38M 7.59M 97.18M 7.65M 7.48M 324M
Net income -10.48M -9.08M -8.5M -7.76M -14.59M -1B -14.84M -99.75M -39.04M -500M -39.36M -38.5M -1.67B -8.23M -7.13M -6.67M -6.09M -11.46M -785M -11.65M -78.31M -30.65M -393M -30.9M -30.22M -1.31B
Net Debt -4.13M -3.57M -3.35M -3.05M -5.74M -394M -5.84M -39.26M -15.37M -197M -15.49M -15.15M -657M -4.33M -3.75M -3.51M -3.2M -6.03M -413M -6.13M -41.2M -16.13M -207M -16.26M -15.9M -690M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-